We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?
Read MoreHide Full Article
Last week, Bristol Myers (BMY - Free Report) reported better-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.80 comfortably beat the Zacks Consensus Estimate of $1.51. In the year-ago quarter, BMY posted an adjusted loss per share of $4.40.
Total revenues of $11.2 billion surpassed the Zacks Consensus Estimate of $10.7 billion. However, revenues were down 6% from the year-ago period’s level due to the impact of generics and Medicare Part D redesign in the Legacy portfolio.
Bristol Myers also raised its annual revenue guidance. However, the stock has been down 4% since the earnings announcement, probably reflecting broader market concerns and investors’ skepticism on BMY’s growth prospects.
Let us analyze BMY’s fundamentals in such a scenario.
Strong growth in Opdivo, Breyanzi, Reblozyl and Camzyos fueled revenue growth in the first quarter.
Revenue growth was solid for the leading immuno-oncology drug Opdivo, driven primarily by volume growth.
The FDA had earlier granted approval to Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. Per BMY, this new subcutaneous formulation of Opdivo should help extend the reach and impact of its immuno-oncology franchise to patients into the next decade. The launch in the United States is progressing well, with early adoption across multiple tumor types. BMY expects physicians to convert approximately 30-40% of patients to this new product.
Thalassemia drug Reblozyl, for which BMY has a collaboration agreement with Merck (MRK - Free Report) , has put up a stellar performance since its approval, driven by strong growth in the first and second-line treatment of myelodysplastic syndromes (MDS)- associated anemia. Higher sales in the United States were related to increased use in the first-line setting. Outside the United States, Reblozyl's strong double-digit sales growth was driven by demand across newly-launched markets in Europe and Japan. The drug is expected to contribute significantly in the coming decade.
Camzyos witnessed strong global demand in the first quarter. Solid momentum due to its compelling efficacy and safety profile in obstructive HCM should further drive growth.
BMY earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults. The drug was approved under the brand name Cobenfy.
The approval of Cobenfy for schizophrenia broadens BMY’s portfolio and validates the acquisition of Karuna Therapeutics.
Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. The initial uptake is encouraging, with sales of $27 million in the first quarter. This drug is expected to contribute meaningfully to BMY’s top line in the coming years as it looks to expand the drug’s label into other indications.
However, BMY recently announced disappointing top-line results from the phase III ARISE study on schizophrenia drug Cobenfy. The study is evaluating the efficacy and safety of the drug as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. Treatment with Cobenfy as an adjunctive demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale total score compared to placebo with an atypical antipsychotic at week six. However, this data did not reach the threshold for statistical significance for the primary endpoint.
The late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos for the treatment of adult patients with symptomatic New York Heart Association (“NYHA”) class II-III non-obstructive hypertrophic cardiomyopathy also did not meet its dual primary endpoints.
Generic Competition for BMY’s Top Drugs: A Headwind
Legacy Portfolio revenues declined 20% in the first quarter due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the U.S. Medicare Part D redesign effect.
Among these, blood thinner medicine Eliquis, for which BMY has a worldwide co-development and co-commercialization agreement with pharma giant Pfizer (PFE - Free Report) , is the biggest contributor to the top line.
Eliquis sales were down 4% due to the impact of Medicare Part D redesign in the United States. The company expects sales to steadily increase in the second half of 2025 due to the elimination of the coverage gap.
BMY Raises Guidance
Bristol-Myers raised its annual revenue guidance to $45.8-$46.8 billion from $45.5 billion on the back of strong performance of the Growth Portfolio, better-than-expected Legacy Portfolio sales in the first quarter of 2025 and a favorable impact of approximately $500 million related to foreign exchange rates.
The company now expects legacy portfolio to decline approximately 16-18% for the year (previous guidance: 18-20%), primarily due to Revlimid's strong performance in the first quarter.
The company now expects adjusted earnings per share to be in the range of $6.70-$7 (previous guidance: $6.55-$6.85). Management added that the stated guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China but do not account for potential pharmaceutical sector tariffs.
BMY’s High Debt Ratio Worrisome
While BMY’s strategy of acquiring companies with promising drugs/candidates is encouraging, it has resulted in colossal debt to finance these acquisitions.
As of March 31, 2025, the company had cash and equivalents of $12.1 billion and a long-term debt of $46.1 billion.
BMY’s Stock Price, Valuation and Estimate Revision
Shares of BMY have lost 13.4% year to date compared with the industry’s decline of 4.4%.
BMY Underperforms Industry, Sector & S&P 500 Index
Image Source: Zacks Investment Research
Going by the price/earnings ratio, BMY’s shares currently trade at 7.31x forward earnings, lower than its mean of 8.59x and the large-cap pharma industry’s 15.70x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 EPS has moved up to $6.79 from $6.77 in the past seven days, while that for 2026 has moved down to $6.04 from $6.06.
BMY’s Estimate Movement
Image Source: Zacks Investment Research
Stay Invested in BMY Stock
Large biotech companies are generally considered safe havens for investors interested in this sector. Drugs like Reblozyl, Breyanzi, Camzyos and Opdualag have enabled BMY to stabilize its revenue base amid generic competition for its legacy drugs. Approval of additional new drugs and label expansion of top drugs should further diversify its pipeline.
However, generic competition is a major headwind for the company and the new drugs will take some time to offset this steep decline. The recent pipeline setbacks weigh on the stock. We recommend prospective investors to wait and watch for the time being.
For investors already owning the stock, staying invested would be a prudent move. The company’s attractive dividend yield (5.18%) is a strong reason for existing investors to stay invested.
Image: Shutterstock
BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?
Last week, Bristol Myers (BMY - Free Report) reported better-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.80 comfortably beat the Zacks Consensus Estimate of $1.51. In the year-ago quarter, BMY posted an adjusted loss per share of $4.40.
Total revenues of $11.2 billion surpassed the Zacks Consensus Estimate of $10.7 billion. However, revenues were down 6% from the year-ago period’s level due to the impact of generics and Medicare Part D redesign in the Legacy portfolio.
Bristol Myers also raised its annual revenue guidance. However, the stock has been down 4% since the earnings announcement, probably reflecting broader market concerns and investors’ skepticism on BMY’s growth prospects.
Let us analyze BMY’s fundamentals in such a scenario.
Newer Drugs Fuel BMY’s Top Line
Growth portfolio primarily comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others.
Strong growth in Opdivo, Breyanzi, Reblozyl and Camzyos fueled revenue growth in the first quarter.
Revenue growth was solid for the leading immuno-oncology drug Opdivo, driven primarily by volume growth.
The FDA had earlier granted approval to Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. Per BMY, this new subcutaneous formulation of Opdivo should help extend the reach and impact of its immuno-oncology franchise to patients into the next decade. The launch in the United States is progressing well, with early adoption across multiple tumor types. BMY expects physicians to convert approximately 30-40% of patients to this new product.
Thalassemia drug Reblozyl, for which BMY has a collaboration agreement with Merck (MRK - Free Report) , has put up a stellar performance since its approval, driven by strong growth in the first and second-line treatment of myelodysplastic syndromes (MDS)- associated anemia. Higher sales in the United States were related to increased use in the first-line setting. Outside the United States, Reblozyl's strong double-digit sales growth was driven by demand across newly-launched markets in Europe and Japan. The drug is expected to contribute significantly in the coming decade.
Camzyos witnessed strong global demand in the first quarter. Solid momentum due to its compelling efficacy and safety profile in obstructive HCM should further drive growth.
BMY earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults. The drug was approved under the brand name Cobenfy.
The approval of Cobenfy for schizophrenia broadens BMY’s portfolio and validates the acquisition of Karuna Therapeutics.
Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. The initial uptake is encouraging, with sales of $27 million in the first quarter. This drug is expected to contribute meaningfully to BMY’s top line in the coming years as it looks to expand the drug’s label into other indications.
However, BMY recently announced disappointing top-line results from the phase III ARISE study on schizophrenia drug Cobenfy. The study is evaluating the efficacy and safety of the drug as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. Treatment with Cobenfy as an adjunctive demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale total score compared to placebo with an atypical antipsychotic at week six. However, this data did not reach the threshold for statistical significance for the primary endpoint.
The late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos for the treatment of adult patients with symptomatic New York Heart Association (“NYHA”) class II-III non-obstructive hypertrophic cardiomyopathy also did not meet its dual primary endpoints.
Generic Competition for BMY’s Top Drugs: A Headwind
Legacy Portfolio revenues declined 20% in the first quarter due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the U.S. Medicare Part D redesign effect.
Among these, blood thinner medicine Eliquis, for which BMY has a worldwide co-development and co-commercialization agreement with pharma giant Pfizer (PFE - Free Report) , is the biggest contributor to the top line.
Eliquis sales were down 4% due to the impact of Medicare Part D redesign in the United States. The company expects sales to steadily increase in the second half of 2025 due to the elimination of the coverage gap.
BMY Raises Guidance
Bristol-Myers raised its annual revenue guidance to $45.8-$46.8 billion from $45.5 billion on the back of strong performance of the Growth Portfolio, better-than-expected Legacy Portfolio sales in the first quarter of 2025 and a favorable impact of approximately $500 million related to foreign exchange rates.
The company now expects legacy portfolio to decline approximately 16-18% for the year (previous guidance: 18-20%), primarily due to Revlimid's strong performance in the first quarter.
The company now expects adjusted earnings per share to be in the range of $6.70-$7 (previous guidance: $6.55-$6.85).
Management added that the stated guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China but do not account for potential pharmaceutical sector tariffs.
BMY’s High Debt Ratio Worrisome
While BMY’s strategy of acquiring companies with promising drugs/candidates is encouraging, it has resulted in colossal debt to finance these acquisitions.
As of March 31, 2025, the company had cash and equivalents of $12.1 billion and a long-term debt of $46.1 billion.
BMY’s Stock Price, Valuation and Estimate Revision
Shares of BMY have lost 13.4% year to date compared with the industry’s decline of 4.4%.
BMY Underperforms Industry, Sector & S&P 500 Index
Image Source: Zacks Investment Research
Going by the price/earnings ratio, BMY’s shares currently trade at 7.31x forward earnings, lower than its mean of 8.59x and the large-cap pharma industry’s 15.70x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 EPS has moved up to $6.79 from $6.77 in the past seven days, while that for 2026 has moved down to $6.04 from $6.06.
BMY’s Estimate Movement
Image Source: Zacks Investment Research
Stay Invested in BMY Stock
Large biotech companies are generally considered safe havens for investors interested in this sector. Drugs like Reblozyl, Breyanzi, Camzyos and Opdualag have enabled BMY to stabilize its revenue base amid generic competition for its legacy drugs. Approval of additional new drugs and label expansion of top drugs should further diversify its pipeline.
However, generic competition is a major headwind for the company and the new drugs will take some time to offset this steep decline. The recent pipeline setbacks weigh on the stock. We recommend prospective investors to wait and watch for the time being.
For investors already owning the stock, staying invested would be a prudent move. The company’s attractive dividend yield (5.18%) is a strong reason for existing investors to stay invested.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.